Page last updated: 2024-08-05 10:51:16
polyol
A compound that contains two or more hydroxy groups.
ChEBI ID: 26191
Members (9)
| Member | Definition | Role |
|---|---|---|
| 2,3,4,5-tetrahydroxypentanal | 2,3,4,5-tetrahydroxypentanal | |
| adriamycinol | A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties. | doxorubicinol |
| filipin | A macrolide that is the major component of a mixture of four isomeric polyene macrolides isolated from Streptomyces filipinensis. | filipin III |
| nosiheptide | Nosiheptide | |
| palytoxin | A polyol marine coelenterate toxin composed of substituted N-3-hydroxypropyl-trans-3-amidoacrylamides and produced by species of Palythoa and Zoanthus soft corals (collectively called zoantharians), either as a defence mechanism or to assist them in capturing prey. An ionophore that forms cation channels through Na+/K+-ATPase, it is a potent vasoconstrictor useful in evaluation of anti-angina agents. It is considered to be one of the most poisonous non-protein substances known, second only to maitotoxin in terms of toxicity in mice. | palytoxin |
| ramoplanin a2 | Ramoplanin | |
| rishitin | Rishitin | |
| terrein | terrein | |
| validamycin a | A member of the class of validamycins that is (1R,2S,3S,4S,6R)-4-amino-6-(hydroxymethyl)cyclohexane-1,2,3-triol in which the hydroxy group at position 1 has been converted to its beta-D-glucoside and in which one of the hydrogens attached to the nitrogen is replaced by a (1R,4R,5R,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)cyclohex-2-en-1-yl group. It is the major validamycin produced by Streptomyces hygroscopicus. | validamycin A |
Research
Studies (823)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 151 (18.35) | 18.7374 |
| 1990's | 123 (14.95) | 18.2507 |
| 2000's | 175 (21.26) | 29.6817 |
| 2010's | 285 (34.63) | 24.3611 |
| 2020's | 89 (10.81) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 12 (1.42%) | 5.53% |
| Reviews | 47 (5.57%) | 6.00% |
| Case Studies | 35 (4.15%) | 4.05% |
| Observational | 2 (0.24%) | 0.25% |
| Other | 748 (88.63%) | 84.16% |